Denali Therapeutics Inc. (FRA:4DN)

Germany flag Germany · Delayed Price · Currency is EUR
17.75
+1.74 (10.87%)
At close: Jan 23, 2026
-20.76%
Market Cap2.86B -5.0%
Revenue (ttm)n/a
Net Income-425.08M
EPS-2.48
Shares Outn/a
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volumen/a
Average Volume77
Open17.75
Previous Close16.01
Day's Range17.75 - 17.75
52-Week Range10.17 - 22.95
Betan/a
RSI63.80
Earnings DateFeb 27, 2026

About Denali Therapeutics

Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; DNL343 eIF2B activator program for amyotrophic lateral sclerosis; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Syndrome A); and DNL310 Tividenofusp alfa, an enzyme r... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2013
Employees 517
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol 4DN
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements